Galenica AG Reports Strong 2025 Performance and Extends Mid‑Term Outlook
Galenica AG, the Swiss pharmacy retailer listed on the SIX Swiss Exchange, announced that it has achieved a robust operating result for the 2025 financial year, prompting an upward revision of its medium‑term guidance. The company’s earnings before interest and taxes (EBIT) rose by 11 %, while the dividend per share increased by 9 %.
The announcement comes amid a broader context of industry consolidation, highlighted by the completion of a consultation process at Bichsel, a subsidiary that has decided to cease its pharmaceutical manufacturing operations. This strategic shift allows Galenica to focus on its core retail and service offerings, potentially improving operational efficiency.
Key Highlights
| Metric | 2025 Actual | 2024 Comparison |
|---|---|---|
| EBIT | +11 % | – |
| Dividend per share | +9 % | – |
| Market price (10 Mar 2026) | 93.45 CHF | – |
| 52‑week high | 103 CHF | – |
| 52‑week low | 76.75 CHF | – |
| Market cap | 4.67 billion CHF | – |
| P/E ratio | 25.5 | – |
Galenica’s performance is consistent with its stated growth strategy, which has been pursued aggressively throughout 2025. By delivering higher earnings and a stronger dividend payout, the company has reinforced investor confidence and positioned itself favorably in a market that has experienced volatility in the Swiss equity index.
Strategic Context
The closure of Bichsel’s manufacturing arm marks a significant pivot in Galenica’s business model. By divesting from production, the company can reallocate capital toward expanding its retail footprint, enhancing digital services, and investing in customer‑centric initiatives. This realignment is expected to contribute to sustained revenue growth and improved profit margins.
Market Reception
While the stock closed at 93.45 CHF on 10 March 2026, its trajectory within the 52‑week range—from a low of 76.75 CHF to a high of 103 CHF—reflects investor optimism about the company’s renewed focus and financial resilience. The price‑earnings ratio of 25.5 positions Galenica among the more valued peers in the health‑care services sector, suggesting that market participants are willing to pay a premium for its disciplined growth outlook.
Outlook
With the mid‑term guidance now elevated, Galenica is expected to maintain its EBIT growth trajectory and continue raising dividends in line with earnings. The company’s emphasis on retail expansion and digital transformation, coupled with the strategic divestiture of Bichsel’s manufacturing operations, provides a clear roadmap for sustaining profitability in the coming years.
